Pharmaceutical – Brains Bioceutical

Pharmaceuticals

Brains Bio is building a development portfolio of cannabinoid-based therapeutics, partner-ready for global market expansion. End-to-end drug development expertise – combining quality, regulatory precision and scientific rigor from discovery through clinical development

State-of-the-Art Development & Manufacturing

Large-scale cannabinoid API production in Kent, England, advancing a diversified portfolio of APIs, formulations and finished products backed by pharmaceutical-grade quality

MANUFACTURING CAPABILITY

Data packages including U.S. DMFs, CEP, EU ASMFs, and IMPD documentation

Robust and scalable manufacture and supply

Eight API and nutraceutical manufacturing lines

Multiple customer and health agency audits

Consistent product quality demonstrated in over 500 batches

Supported by network of approved GMP CDMOs

Clinical Pipeline Architecture

Risk-Managed Drug Development

Near-term programs in submission preparation

IP-protected assets, built on Brains Bio science and API supply, advanced with low cash exposure through milestone-based investment and non-dilutive funding.

Active Phase 3 programs

Glaucoma (FDA) and insomnia (TGA), both with completed late-stage clinical work and dossiers in preparation.

Platform for continued development

Opioid use disorder, supported by approximately $18M in non-dilutive NIH grant funding, and epilepsy, pursuing an accelerated 505(b)(2) regulatory pathway.

Strategic & Supply Relationships with Leading Multinationals

Strategic customer relationships leveraging synergies across customers’ respective programs and activities in RoW territories

Jas Kalsi

An experienced Chartered Professional Accountant with over 30 years of experience in providing personal and corporate taxation, corporate restructuring, financing, public offering and human resources management services. Kalsi is the Chief Financial Officer for Brains Bioceutical Corp., a global manufacturer of naturally-sourced active pharmaceutical ingredients (APIs). In this role, Kalsi is responsible for overseeing and managing the fiscal health of the group, implementing best practices with respect to finance, accounting and internal controls, obtaining funding, providing recommendations on mergers and acquisitions and working collaboratively with the CEO and Board of Directors on strategy. In addition, Kalsi will be responsible to regulatory entities and authorities, including any security exchange commissions.

Kalsi was an audit partner at KPMG focusing on small, medium and large private, government sector and public audit clients. He was the Human Resource Manager in charge of recruiting, staff development and training, and a member of KPMG’s Professional Practice Group. Subsequent to KPMG, Kalsi was the Chief Financial Officer / Chief Executive Officer of a variety of private companies including 6.5 years with a pharmaceutical fulfillment provider and API developer.

Kalsi has a proven track record in hiring top-level senior executives, restructuring companies to minimize tax and maximize cash flows, raising financing and creating a cohesive culture.

Kalsi has a passion for wellness and has created several initiatives and partnered with several leading-edge individuals to help people create and enjoy the best versions of themselves. He sees the use cannabinoids as a major tool to facilitate one’s optimum lifestyle.

With the team and infrastructure in place, Brains Bioceutical has quickly become an industry leader in both the nutraceutical and pharmaceutical cannabinoid industries, with several clinical trials and academic studies underway evaluating the efficacy of cannabinoids to treat major diseases. Under Kalsi’s leadership, Brains Bioceutical has already established market dominance, as it is the only company in the world to sell bulk API commercially around the world, supporting both the pharmaceutical and wellness sectors. With ambitious plans to expand Brains Bioceutical into a global biotech company specializing in cannabinoid health and wellness solutions, Kalsi is pioneering a new frontier in medicinal and wellness solutions across the world.

Pharmaceuticals

Brains Bio is building a development portfolio of cannabinoid-based therapeutics, partner-ready for global market expansion. End-to-end drug development expertise – combining quality, regulatory precision and scientific rigor from discovery through clinical development

State-of-the-Art Development & Manufacturing

MANUFACTURING CAPABILITY

Clinical Pipeline Architecture

Risk-Managed Drug Development

Near-term programs in submission preparation

Active Phase 3 programs

Platform for continued development

Strategic & Supply Relationships with Leading Multinationals

Contact Us

General Inquiries:

Pharmaceuticals

Brains Bio is building a development portfolio of cannabinoid-based therapeutics, partner-ready for global market expansion. End-to-end drug development expertise – combining quality, regulatory precision and scientific rigor from discovery through clinical development

State-of-the-Art Development & Manufacturing

MANUFACTURING CAPABILITY

Clinical Pipeline Architecture​​

Risk-Managed Drug Development

Near-term programs in submission preparation

Active Phase 3 programs

Platform for continued development

Strategic & Supply Relationships with Leading Multinationals

Contact Us

General Inquiries:

Jas Kalsi

Chief Financial Officer

Jennifer Archibald

Chief Financial Officer

Barinder Bhullar

Senior Vice President, Corporate Affairs

William Purves

Chief Commercial Officer

Gurdeep Bains

VP of Business Development

Jorja’s Story

A father’s journey to saving his daughter’s life

Dr. Mike Bowen

Dr. Jack Taunton

Dr. Sharon Gurm

Dr. David Putrino

Dr. Gerry Ramogida

Norma Sebestyen

Dean Billington

COO

Terry O’Regan

President

Rick Brar

CEO and Chairman

Clinical Pipeline Architecture